


COVID-19 could trigger “backshoring” of pharmaceutical manufacturing from India and China

Primarily driven by lower prices for active pharmaceutical ingredients (APIs) manufacturing has mainly moved to India and China over the past decades. Estimates put about 70-80% of production for active pharmaceutical ingredients in the two Asian countries, which politicians in Europe and North America regard as a considerable geopolitical challenge. As governments scramble to get sufficient medical supplies to manage the current situation, the corona crisis could become a turning point for the pharmaceutical industry – potentially reversing the eastward outsourcing trend.

“The issue of dependency of the EU vis-à-vis China, and other countries [...] was on the table before COVID-19,” said [Stella Kyriakides](#), European Commissioner for Health and Food Safety and one of the key officials in Brussels’ pandemic response. “[The crisis] has highlighted this problem and we need to look at it, we need to ensure that we reduce our dependency on other countries.”¹


India and China have become the powerhouse of pharmaceutical manufacturing over the past decades, the majority of active pharmaceutical ingredients (APIs) in drugs worldwide are nowadays produced foremost in these two countries. Taking the commonly known fever and pain medication Paracetamol (Acetaminophen) as an example, eight of the twelve leading API manufacturers supplying Europe and the United States are based in India and China (compare figure 1).

Paracetamol API manufacturers supplying Europe and the United States




Sources: QYOBO platform, based on valid USDMF and CEP filings issued by the Food and Drug Administration (FDA) and the European Directorate for the Quality of Medicines (EDQM) Figure 1

But this is not the only example for India's and China's increasing importance in API manufacturing. As for the anti-inflammatory remedy Diclofenac, a net of eight manufacturing sites were added in India and China (four in each country) between 2005 and 2020 whereas a single production facility was added in other parts of the world (as seen in figure 2). The type 2 diabetes treatment Metformin experienced an even more significant increase of 19 additional sites in India and China (18 in India and 1 in China) compared to five in other countries.



The main reason for this development are more competitive prices. As governments and health insurance companies worldwide expanded the use of public tenders and RFPs to keep rising health care costs in check, price became the primary deciding factor. Market participants such as generics companies were thus forced to work with the most affordable sources. This resulted in the outsourcing or the transfer of the companies' own API production to lower cost countries like India and China. This cost advantage can be quite significant as shown by Paracetamol which could be sourced at a 30-50% lower price from India and China compared to suppliers in North America over the last four years.



Already in 2009, The New York Times stated that “experts and lawmakers are growing more and more concerned that the nation (United States) is far too reliant on medicine from abroad” ². Little has changed since – even as Western policy makers became progressively worried about the dependency on India and China in the context of increasing drug shortages over the past years. ³⁻⁵ Severely demonstrating the fragility of global supply chains, the corona crisis gives a new dynamic to the discussion. As governments scramble to get sufficient medical supplies to manage the ongoing situation, export restrictions issued by the Indian administration for some essential APIs (including Paracetamol and Metformin) ⁶ have done little to increase confidence in the current system. While some of these restrictions were lifted four weeks later, ⁷ to date, the export of Paracetamol remains restricted. As a result, the corona pandemic could become a crucial turning point for the pharmaceutical supply chain as Western countries are looking to bring manufacturing back from Asia (dubbed “backsourcing”).

Politicians in Europe and North America have identified the reliance on third countries for pharmaceutical manufacturing as a geopolitical challenge. In a [meeting](#) on March 12, 2020, the Pharmaceutical Committee – an expert group of the EU Health and Food Safety Commission department of Commissioner Kyriakides – decided to “assess the EU’s dependency on manufacturing of active pharmaceutical ingredients in third countries, as this is one important cause of shortages”. With a similar motivation, U.S. senators Rubio, Warren, Cramer, Murphy and Kaine introduced the “[Strengthening America’s Supply Chain and National Security Act](#)” on April 19, 2020, to analyze the “reliance on pharmaceutical products” from “China and any other country as determined by the Secretary of Defense for national security purposes”.

In summary, the corona crisis could become a turning point for the pharmaceutical industry, potentially reversing the eastward outsourcing trend. Whether this transition will take place and at which speed will depend on the relative importance of supply security compared to cost in the aftermath of the COVID-19 pandemic.

For further information please contact:

Ms. Thuy Linh Nguyen, Corporate Communications

communication@qyobo.com

www.qyobo.com

About QYOBO:

QYOBO GmbH is a Munich-based tech company providing actionable market insights on the API, excipient and chemical markets. The company has developed proprietary big data algorithms to process and enrich data from a large variety of distributed data sources. Leveraging this expertise, QYOBO provides its clients with a one-stop solution to benchmark prices, analyze trends, identify relevant trading partners and streamline adjacent sales and procurement workflows.

Sources:

QYOBO platform, Food and Drug Administration (FDA), European Directorate for the Quality of Medicines (EDQM).

¹ Financial Times, 20 April 2020.
[Covid-19 exposes EU’s reliance on drug imports.](#)

³ Deutschlandfunk, 21 November 2019.
[Lieferengpässe bei Medikamenten.](#)

⁵ Le Figaro, 2 October 2018.
[Le Sénat dénonce la pénurie de vaccins et de médicaments.](#)

⁷ Government of India, 6 April 2020.
[Directorate General of Foreign Trade, Notification 02/2015-2020.](#)

² New York Times, 19 January 2009.
[Drug Making’s Move Abroad Stirs Concerns.](#)

⁴ Le Figaro, 11 August 2019.
[Les délocalisations à l’origine de la pénurie de médicaments en France.](#)

⁶ Government of India, 3 March 2020.
[Directorate General of Foreign Trade, Notification 50/2015-20.](#)

Disclaimer:

This assessment has been prepared adhering to the highest quality standards based on a variety of external data sources (see sources) with the purpose of making distributed information accessible to a broader audience.

The information contained in this document is provided on an “as is” basis and QYOBO GmbH assumes no responsibility or liability for the completeness, accuracy, usefulness or timeliness of the information provided. This article contains links to external websites operated by third parties upon which QYOBO GmbH has no influence. QYOBO GmbH does not assume any guarantee or liability for third party content.